G. Couvreur and P. Moreau, La sclérose en plaques Défic Mot Situat Handicaps Asp Sociaux Psychol Médicaux Tech Législatifs Troubl Assoc Éditions Assoc Paralys Fr, pp.178-85, 2002.

D. Brassat, Physiopathologie de la scl??rose en plaques, La Presse M??dicale, vol.39, issue.3, pp.341-349, 2010.
DOI : 10.1016/j.lpm.2009.12.001

P. Gallien, N. B. Guichet, and A. , Le point sur la scl??rose en plaques, Kin??sith??rapie, la Revue, vol.12, issue.125, pp.17-22, 2012.
DOI : 10.1016/j.kine.2012.04.005

V. Damotte, Génétique de la Sclérose En Plaques: Héritabilité manquante et Charge génétique, 2013.

A. Fromont and T. Moreau, Sclérose en plaques : des formes bénignes aux formes rapidement invalidantes. Médecine, pp.162-168, 2007.

C. Confavreux and S. Vukusic, Age at disability milestones in multiple sclerosis, Brain, vol.129, issue.3, pp.595-605, 2006.
DOI : 10.1093/brain/awh714

O. Lyon-caen and M. Clanet, La sclérose en plaques, John Libbey Eurotext, 1997.

M. Soilu-hänninen, L. Airas, I. Mononen, A. Heikkilä, M. Viljanen et al., 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis, Multiple Sclerosis, vol.11, issue.3, pp.266-71, 2005.
DOI : 10.1191/1352458505ms1157oa

K. Munger, S. Zhang, E. O-'reilly, M. Hernan, M. Olek et al., Vitamin D intake and incidence of multiple sclerosis, Neurology, vol.62, issue.1, pp.60-65, 2004.
DOI : 10.1212/01.WNL.0000101723.79681.38

L. Magy, La scl??rose en plaques, Actualit??s Pharmaceutiques Hospitali??res, vol.5, issue.19, pp.14-23, 2009.
DOI : 10.1016/S1769-7344(09)70013-7

S. Hucke, H. Wiendl, and L. Klotz, Implications of dietary salt intake for multiple sclerosis pathogenesis, Multiple Sclerosis Journal, vol.18, issue.2, pp.133-142
DOI : 10.1136/bmj.39147.604896.55

C. Wu, N. Yosef, T. Thalhamer, C. Zhu, S. Xiao et al., Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1, Nature, vol.16, issue.7446, pp.513-520, 2013.
DOI : 10.1038/nature11984

M. Kleinewietfeld, A. Manzel, J. Titze, H. Kvakan, N. Yosef et al., Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells, Nature, vol.197, issue.7446, pp.518-540, 2013.
DOI : 10.1038/nature11868

A. Rolland, E. Jouvin-marche, M. Saresella, P. Ferrante, R. Cavaretta et al., Correlation between disease severity and in vitro cytokine production mediated by MSRV (Multiple Sclerosis associated RetroViral element) envelope protein in patients with multiple sclerosis, Journal of Neuroimmunology, vol.160, issue.1-2, pp.195-203, 2005.
DOI : 10.1016/j.jneuroim.2004.10.019

C. Confavreux, S. Suissa, P. Saddier, V. Bourdès, and S. Vukusic, Vaccinations and the Risk of Relapse in Multiple Sclerosis, New England Journal of Medicine, vol.344, issue.5, pp.319-345, 2001.
DOI : 10.1056/NEJM200102013440501

B. Pd and D. A. De-aguilar-j-lg, Les maladies neurologiques à travers les études pan-génomiques (Genome Wide Association Studies-GWAS), Lett L?, vol.62, p.12, 2011.

R. Bakshi, Z. Shaikh, R. Miletich, D. Czarnecki, J. Dmochowski et al., Fatigue in multiple sclerosis and its relationship to depression and neurologic disability, Multiple Sclerosis, vol.6, issue.3, pp.181-186, 2000.
DOI : 10.1191/135245800701566052

M. Schluep and R. Du-pasquier, Traitement de la sclérose en plaques: nouveautés et complications, Neurologie, vol.384, issue.17, pp.940-943, 2013.

A. Fromont and T. Moreau, Sclérose en plaques : traitements d'aujourd'hui et de demain. Médecine, Feb, vol.13, issue.2, pp.61-67, 2007.

A. Fromont and T. Moreau, Une recherche dynamique permet d'envisager des avancées thérapeutiques significatives, 2009.

F. Durand-dubief and L. Gignoux, La sclérose en Plaques les traitements, Réseau Rhône Alpes SEP

P. Yudkin, G. Ellison, A. Ghezzi, D. Goodkin, R. Hughes et al., Overview of azathioprine treatment in multiple sclerosis. The Lancet, pp.1051-1056, 1991.

D. Goodkin, R. Rudick, S. Medendorp, M. Daughtry, K. Schwetz et al., Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis, Annals of Neurology, vol.29, issue.1, pp.30-40, 1995.
DOI : 10.1002/ana.410370108

L. Durelli, E. Verdun, P. Barbero, M. Bergui, E. Versino et al., Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN), The Lancet, vol.359, issue.9316, pp.1453-60, 2002.
DOI : 10.1016/S0140-6736(02)08430-1

L. Jacobs, R. Beck, J. Simon, R. Kinkel, C. Brownscheidle et al., Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis, New England Journal of Medicine, vol.343, issue.13, pp.898-904, 2000.
DOI : 10.1056/NEJM200009283431301

L. Kappos, Placebo-controlled multicentre randomised trial of interferon ?-1b in treatment of secondary progressive multiple sclerosis. The Lancet, pp.1491-1498, 1998.

C. Papeix, C. Lubetzki, and O. Lyon-caen, Traitements actuels de la sclérose en plaques. Presse Médicale, pp.381-389, 2010.

Y. Michiels and M. Voirin, Les nouvelles formes m??dicamenteuses orales dans la scl??rose en plaques, Actualit??s Pharmaceutiques, vol.54, issue.547, pp.41-46
DOI : 10.1016/j.actpha.2015.03.033

G. Mathey, Sclérose en Plaques: les nouveaux traitements, 2015.

O. Stüve, S. Youssef, L. Steinman, and S. Zamvil, Statins as potential therapeutic agents in neuroinflammatory disorders, Current Opinion in Neurology, vol.16, issue.3, pp.393-401, 2003.
DOI : 10.1097/00019052-200306000-00021

R. Burt, Y. Loh, B. Cohen, D. Stefosky, R. Balabanov et al., Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study, The Lancet Neurology, vol.8, issue.3, pp.244-53, 2009.
DOI : 10.1016/S1474-4422(09)70017-1

A. Goodman, T. Brown, L. Krupp, R. Schapiro, S. Schwid et al., Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial, The Lancet, vol.373, issue.9665, pp.732-740, 2009.
DOI : 10.1016/S0140-6736(09)60442-6

C. Brady, R. Dasgupta, C. Dalton, O. Wiseman, K. Berkley et al., An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis, Multiple Sclerosis Journal, vol.192, issue.4, pp.425-458, 2004.
DOI : 10.1093/brain/124.5.962

D. Fassin, Décrire: entretien et observation, J.-M, 2009.

H. Panitch, D. Goodin, G. Francis, P. Chang, P. Coyle et al., Randomized, comparative study of interferon ??-1a treatment regimens in MS: The EVIDENCE Trial, Neurology, vol.59, issue.10, pp.1496-506, 2002.
DOI : 10.1212/01.WNL.0000034080.43681.DA